Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso

BMC Infectious Diseases

Volumn 9, Issue , 2009, Pages 142-

  Miotto, Paolo ^a   Saleri, Nuccia ^b,c   Dembelé, Mathurin ^c   Ouedraogo, Martial ^d   Badoum, Gisèle ^d   Pinsi, Gabriele ^b   Migliori, Giovanni B ^e   Matteelli, Alberto ^b   Cirillo, Daniela M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c MINISTÈRE DE LA SANTÉ   (Burkina Faso)

^d UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^e IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; BACTERIAL DNA; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BURKINA FASO; CLINICAL PROTOCOL; CONTROLLED STUDY; GENE MUTATION; HETEROZYGOTE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT CARE; PROMOTER REGION; SPUTUM SMEAR; ANALYTICAL EQUIPMENT; DRUG EFFECT; EVALUATION; GENETICS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; NUCLEOTIDE SEQUENCE; SENSITIVITY AND SPECIFICITY; SPUTUM;

ANTITUBERCULAR AGENTS; BURKINA FASO; DNA MUTATIONAL ANALYSIS; DNA, BACTERIAL; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; REAGENT KITS, DIAGNOSTIC; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 70349757526     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-9-142     Document Type: Article

References (30)

1. World Health Organization WHO Report 2007. Global tuberculosis control. Surveillance, planning, financing 2007, WHO; Geneva.
2. World Health Organization The global MDR-TB and XDR-TB response plan, 2007-2008 2007, WHO; Geneva.
3. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, Williams BG, Dye C. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006, 194:479-485. 10.1086/505877, 16845631.
4. Davies PD. The world-wide increase in tuberculosis: how demographic changes, HIV infection and increasing numbers in poverty are increasing tuberculosis. Ann Med 2003, 35:235-243. 10.1080/07853890310005713, 12846265.
5. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580. 10.1016/S0140-6736(06)69573-1, 17084757.
6. Sotgiu G, Ferrara G, Matteelli A, Richardson MD, Centis R, Ruesch-Gerdes S, Toungoussova O, Zellweger J-P, Spanavello A, Cirillo D, Lange C, Migliori GB. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009, 33:1.
7. Adjers-Koskela K, Katila ML. Susceptibility testing with the manual mycobacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis. J Clin Microbiol 2003, 41:1235-1239. 10.1128/JCM.41.3.1235-1239.2003, 150305, 12624056.
8. Angeby KA, Werngren J, Toro JC, Hedstrom G, Petrini B, Hoffner SE. Evaluation of the BacT/ALERT 3D system for recovery and drug susceptibility testing of Mycobacteriumtuberculosis. Clin Microbiol Infect 2003, 9:1148-1152. 10.1046/j.1469-0691.2003.00783.x, 14616736.
9. Piersimoni C, Olivieri A, Benacchio L, Scarparo C. Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J Clin Microbiol 2006, 44:20-28. 10.1128/JCM.44.1.20-28.2006, 1351976, 16390942.
10. World Health Organization, StopTB Partnership Global plan to stop TB 2006-2015 2006, WHO; Geneva.
11. Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006, 367:952-955. 10.1016/S0140-6736(06)68392-X, 16546550.
12. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic?. Eur Respir J 2007, 29:423-427. 10.1183/09031936.00001307, 17329486.
13. Migliori GB, Matteelli A, Cirillo D, Pai M. Diagnosis ofmultidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current standards and challenges. Can J Infect Dis Med Microbiol 2008, 19:169-172. 2605858, 19352448.
14. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev Mol Diagn 2006, 6:423-432. 10.1586/14737159.6.3.423, 16706744.
15. Perkins MD, Cunningham J. Facing the crisis: improvingthe diagnosis of tuberculosis in the HIV era. J Infect Dis 2007, 196(Suppl 1):S15-27. 10.1086/518656, 17624822.
16. Drobniewski FA, Hoffner S, Rusch-Gerdes S, Skenders G, Thomsen V. Recommended standards for modern tuberculosis laboratory services in Europe. Eur Respir J 2006, 28:903-909. 10.1183/09031936.06.00084906, 16899481.
17. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008, 177:787-792. 10.1164/rccm.200709-1436OC, 18202343.
18. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation ofthe GenoType® MTBDR plus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007, 45:2635-2640. 10.1128/JCM.00521-07, 1951233, 17537937.
19. World Health Organization Global Tuberculosis Control 2008. Surveillance, Planning, Financing 2008, WHO; Geneva.
20. Joint United Nations Programme on HIV/AIDS (UNAIDS) Report on the HIV/AIDS epidemic 2008 2008, WHO; Geneva.
21. National Tuberculosis Program, Ministry of Health Burkina Faso Plan d'action 2009 du Programme National Tuberculose. Ouagadougou, Burkina Faso 2009,
22. World Health Organization Implementing the WHO Stop TBstrategy. A handbook for national tuberculosis control programmes 2008, WHO; Geneva.
23. World Health Organization Guidelines for theprogrammatic management of drug resistant tuberculosis - emergency update 2008 2008, WHO; Geneva.
24. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008, 32:1165-1174. 10.1054/tuld.1998.0002, 18614561.
25. World Health Organization Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement. 2008, WHO; Geneva.
26. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998, 79:3-29. 10.1054/tuld.1998.0002, 10645439.
27. Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996, 40:2655-2657. 163595, 8913484.
28. Ohno H, Koga H, Kohno S, Tashiro T, Hara K. Relationshipbetween rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother 1996, 40:1053-1056. 10.1054/drup.2001.0196, 163262, 8849230.
29. World Health Organization Laboratory Services in Tuberculosis Control - Culture Part III 1998, WHO; Geneva.
30. Baquero F. Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resist Updat 2001, 4:93-105. 10.1054/drup.2001.0196, 11512526.